

September 20, 2018

Michael F. Kanan  
Senior Vice President and Chief Financial Officer  
Avadel Pharmaceuticals plc  
Block 10-1  
Blanchardstown Corporate Park  
Ballycoolin  
Dublin 15  
Ireland

Re: Avadel Pharmaceuticals plc  
Form 10-K for the Fiscal Year Ended December 31, 2017  
Filed March 16, 2018 and Amended April 30, 2018  
Form 10-Q for the Quarterly Period Ended June 30, 2018  
Filed August 7, 2018  
File No. 001-37977

Dear Mr. Kanan:

We have limited our review of your filings to the financial statements and related disclosures and have the following comment. In our comment, we ask you to provide us with information so we may better understand your disclosure.

Please respond to this comment within 10 business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response.

After reviewing your response to this comment, we may have additional comments.

Form 10-Q for the Quarterly Period Ended June 30, 2018

Notes to the Unaudited Condensed Consolidated Financial Statements  
Note 3: Revenue Recognition  
Periods commencing January 1, 2018  
Reserves to reduce Gross Revenues to Net Revenues, page 11

1. Regarding your product sale revenue, please tell us the amount of each adjustment

Michael F. Kanan  
Avadel Pharmaceuticals plc  
September 20, 2018  
Page 2

recorded during 2018 to your gross-to-net variable consideration estimates made as of January 1, 2018 upon adoption of ASC 606 and your consideration for disclosing this information under ASC 606-10-50-10b and 50-12A. In your response, tell us the amount, if any, you reflected in 2018 for any price concessions for inventory in the distribution channel and recorded as revenue as of the January 1, 2018 ASC 606 adoption date for Bloxiverz or Akovaz given the increased competition for these products.

In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

You may contact Mark Brunhofer at (202) 551-3638 or Mary Mast at (202) 551-3613 with any questions.

FirstName LastNameMichael F. Kanan  
Comapany NameAvadel Pharmaceuticals plc  
Corporation Finance  
September 20, 2018 Page 2  
Healthcare & Insurance  
FirstName LastName

Sincerely,  
Division of  
Office of